• Consensus Rating: Buy
  • Consensus Price Target: $53.50
  • Forecasted Upside: 593.01 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$7.72
▼ -0.17 (-2.15%)

This chart shows the closing price for ALVR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AlloVir Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALVR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALVR

Analyst Price Target is $53.50
▲ +593.01% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for AlloVir in the last 3 months. The average price target is $53.50, with a high forecast of $130.00 and a low forecast of $23.00. The average price target represents a 593.01% upside from the last price of $7.72.

This chart shows the closing price for ALVR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in AlloVir. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/9/2022Morgan StanleyLower TargetOverweight$32.00 ➝ $27.00Low
7/28/2022SVB LeerinkLower TargetOutperform$30.00 ➝ $23.00Low
5/18/2022Piper SandlerLower TargetOverweight$55.00 ➝ $34.00High
2/10/2022SVB LeerinkLower TargetOutperform$32.00 ➝ $30.00High
2/1/2022BMO Capital MarketsInitiated CoverageOutperform$130.00Medium
1/18/2022Morgan StanleyLower TargetOverweight$48.00 ➝ $45.00High
12/17/2021SVB LeerinkLower TargetOutperform$37.00 ➝ $32.00High
11/8/2021SVB LeerinkLower TargetOutperform$41.00 ➝ $37.00High
10/12/2021Morgan StanleyBoost TargetOverweight$47.00 ➝ $48.00Low
9/29/2021Morgan StanleyBoost TargetOverweight$175.00 ➝ $225.00Medium
8/22/2021SVB LeerinkInitiated CoverageBuyHigh
8/18/2021Morgan StanleyLower TargetOverweight$50.00 ➝ $47.00Medium
5/6/2021SVB LeerinkBoost TargetOutperform$41.00 ➝ $42.00Low
4/19/2021Morgan StanleyBoost TargetOverweight$49.00 ➝ $50.00Medium
2/11/2021Piper SandlerBoost Target$52.00 ➝ $55.00Low
8/24/2020Piper SandlerInitiated CoverageOverweightHigh
8/24/2020JPMorgan Chase & Co.Initiated CoverageOverweight$50.00Low
8/24/2020SVB LeerinkInitiated CoverageOutperform$41.00Low
8/24/2020Morgan StanleyInitiated CoverageOverweight$49.00High
1/7/2019Bank of AmericaUpgradeNeutral ➝ BuyN/A
7/10/2018The Goldman Sachs GroupInitiated CoverageNeutralN/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/8/2022
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/7/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/7/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/6/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/6/2022
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/5/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/4/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/4/2022

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
AlloVir logo
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $7.72
Low: $7.26
High: $8.03

50 Day Range

MA: $7.40
Low: $4.59
High: $8.79

52 Week Range

Now: $7.72
Low: $3.17
High: $26.38

Volume

555,258 shs

Average Volume

885,292 shs

Market Capitalization

$718.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Frequently Asked Questions

What sell-side analysts currently cover shares of AlloVir?

The following Wall Street analysts have issued stock ratings on AlloVir in the last year: BMO Capital Markets, Morgan Stanley, Piper Sandler, and SVB Leerink LLC.
View the latest analyst ratings for ALVR.

What is the current price target for AlloVir?

4 Wall Street analysts have set twelve-month price targets for AlloVir in the last year. Their average twelve-month price target is $53.50, suggesting a possible upside of 593.0%. BMO Capital Markets has the highest price target set, predicting ALVR will reach $130.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $23.00 for AlloVir in the next year.
View the latest price targets for ALVR.

What is the current consensus analyst rating for AlloVir?

AlloVir currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALVR will outperform the market and that investors should add to their positions of AlloVir.
View the latest ratings for ALVR.

What other companies compete with AlloVir?

How do I contact AlloVir's investor relations team?

AlloVir's physical mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The company's listed phone number is 617-433-2605 and its investor relations email address is [email protected] The official website for AlloVir is www.allovir.com. Learn More about contacing AlloVir investor relations.